Trial reportDrug design, development and therapy2026
EC
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The aim was to evaluate its antinociceptive potency by comparing the effect of oliceridine and sufentanil on the half maximal effective concentration (EC Patients and methods: A total of 120 patients scheduled for thyroid nodulectomy were randomized into four groups: (i) control group, (ii) sufentanil group, (iii) oliceridine 0.015 mg/kg group, and (iv) oliceridine 0.03 mg/kg group. The initial dosage of remifentanil for induction of general anesthesia was 3 ng/mL. The subsequent infusion dosage of remifentanil was adjusted based on the response to endotracheal intubation in the previous patient in the group, defined as a ≥ 15% change in heart rate (HR) or mean arterial pressure (MAP) before and after intubation. Adjustments were made in increments or decrements of 0.2 ng/mL. The control group received no additional medication, whereas the sufentanil group was administered a 0.15 μg/kg intravenous (IV) bolus of sufentanil. The two oliceridine groups received IV boluses of oliceridine either 0.015 mg/kg or 0.03 mg/kg respectively. Postoperative airway complications, encompassing hoarseness, sore throat, and dysphonia, were also documented. Results: The EC Conclusion: The effect of 0.03 mg/kg oliceridine is similar to 0.15 μg/kg sufentanil in reducing the EC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.